|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2.
|
Mao L, Hong WK and Papadimitrakopoulou VA:
Focus on head and neck cancer. Cancer Cell. 5:311–316. 2004.
View Article : Google Scholar
|
|
3.
|
Henderson YC, Wang E and Clayman GL:
Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in
head and neck squamous cell carcinomas. Laryngoscope.
108:1553–1556. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Shao X, Tandon R, Samara G, Kanki H, Yano
H, Close LG, Parsons R and Sato T: Mutational analysis of the PTEN
gene in head and neck squamous cell carcinoma. Int J Cancer.
77:684–688. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Lee JI, Soria JC, Hassan KA, El-Naggar AK,
Tang X, Liu DD, Hong WK and Mao L: Loss of PTEN expression as a
prognostic marker for tongue cancer. Arch Otolaryngol Head Neck
Surg. 127:1441–1445. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kwon CH, Zhao D, Chen J, Alcantara S, Li
Y, Burns DK, Mason RP, Lee EY, Wu H and Parada LF: Pten
haploinsufficiency accelerates formation of high-grade
astrocytomas. Cancer Res. 68:3286–3294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Alimonti A, Carracedo A, Clohessy JG,
Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ,
Brogi E, Richardson AL, Zhang J and Pandolfi PP: Subtle variations
in Pten dose determine cancer susceptibility. Nat Genet.
42:454–458. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Vazquez F and Sellers WR: The PTEN tumor
suppressor protein: an antagonist of phosphoinositide 3-kinase
signaling. Biochim Biophys Acta. 1470:21–35. 2000.PubMed/NCBI
|
|
9.
|
Gu J, Tamura M and Yamada KM: Tumor
suppressor PTEN inhibits integrin- and growth factor-mediated
mitogen-activated protein (MAP) kinase signaling pathways. J Cell
Biol. 143:1375–1383. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Dey N, Crosswell HE, De P, Parsons R, Peng
Q, Su JD and Durden DL: The protein phosphatase activity of PTEN
regulates SRC family kinases and controls glioma migration. Cancer
Res. 68:1862–1871. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Tamura M, Gu J, Danen EH, Takino T,
Miyamoto S and Yamada KM: PTEN interactions with focal adhesion
kinase and suppression of the extracellular matrix-dependent
phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol
Chem. 274:20693–20703. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Haier J and Nicolson GL: PTEN regulates
tumor cell adhesion of colon carcinoma cells under dynamic
conditions of fluid flow. Oncogene. 21:1450–1460. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhou
Y, Rychahou PG and Evers BM: PTEN loss induces
epithelial-mesenchymal transition in human colon cancer cells.
Anticancer Res. 29:4439–4449. 2009.PubMed/NCBI
|
|
14.
|
Mriouah J, Boura C, Pinel S, Chretien AS,
Fifre A, Merlin JL and Faivre B: Cellular response to cetuximab in
PTEN-silenced head and neck squamous cell carcinoma cell line. Int
J Oncol. 37:1555–1563. 2010.PubMed/NCBI
|
|
15.
|
Jouan-Hureaux V, Boura C, Merlin JL and
Faivre B: Modulation of endothelial cell network formation in vitro
by molecular signaling of head and neck squamous cell carcinoma
(HNSCC) exposed to cetuximab. Microvasc Res. 83:131–137. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Labussière M, Pinel S, Vandamme M, Plénat
F and Chastagner P: Radiosensitizing properties of bortezomib
depend on therapeutic schedule. Int J Radiat Oncol Biol Phys.
79:892–900. 2011.PubMed/NCBI
|
|
17.
|
Thiery JP, Acloque H, J Huang RY and Nieto
MA: Epithelialmesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View
Article : Google Scholar
|
|
19.
|
Durand MK, Bodker JS, Christensen A,
Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen
KE, Skeldal S, Wind T and Andreasen PA: Plasminogen activator
inhibitor-I and tumour growth, invasion, and metastasis. Thromb
Haemost. 91:438–449. 2004.PubMed/NCBI
|
|
20.
|
Gimm O, Perren A, Weng LP, Marsh DJ, Yeh
JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL,
Robinson BG, Komminoth P, Dralle H and Eng C: Differential nuclear
and cytoplasmic expression of PTEN in normal thyroid tissue, and
benign and malignant epithelial thyroid tumors. Am J Pathol.
156:1693–1700. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Liu JL, Sheng X, Hortobagyi ZK, Mao Z,
Gallick GE and Yung WK: Nuclear PTEN-mediated growth suppression is
independent of Akt down-regulation. Mol Cell Biol. 25:6211–6224.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ginn-Pease ME and Eng C: Increased nuclear
phosphatase and tensin homologue deleted on chromosome 10 is
associated with G0-G1 in MCF-7 cells. Cancer Res. 63:282–286.
2003.PubMed/NCBI
|
|
23.
|
Vitolo MI, Weiss MB, Szmacinski M, Tahir
K, Waldman T, Park BH, Martin SS, Weber DJ and Bachman KE: Deletion
of PTEN promotes tumorigenic signaling, resistance to anoikis, and
altered response to chemotherapeutic agents in human mammary
epithelial cells. Cancer Res. 69:8275–8283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Braakhuis BJ, Brakenhoff RH and Leemans
CR: Treatment choice for locally advanced head and neck cancers on
the basis of risk factors: biological risk factors. Ann Oncol.
23:173–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wang H, Quah SY, Dong JM, Manser E, Tang
JP and Zeng Q: PRL-3 down-regulates PTEN expression and signals
through PI3K to promote epithelial-mesenchymal transition. Cancer
Res. 67:2922–2926. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Craene BD and Berx G: Regulatory networks
defining EMT during cancer initiation and progression. Nat Rev
Cancer. 13:97–110. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Li Z, Wang L, Zhang W, Fu Y, Zhao H, Hu Y,
Prins BP and Zha X: Restoring E-cadherin-mediated cell-cell
adhesion increases PTEN protein level and stability in human breast
carcinoma cells. Biochem Biophys Res Commun. 363:165–170. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Lau MT, Klausen C and Leung PC: E-cadherin
inhibits tumor cell growth by suppressing PI3K/Akt signaling via
β-catenin-Egr1-mediated PTEN expression. Oncogene. 30:2753–2766.
2011.PubMed/NCBI
|
|
29.
|
Fournier MV, Fata JE, Martin KJ, Yaswen P
and Bissell MJ: Interaction of E-cadherin and PTEN regulates
morphogenesis and growth arrest in human mammary epithelial cells.
Cancer Res. 69:4545–4552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kotelevets L, van Hengel J, Bruyneel E,
Mareel M, van Roy F and Chastre E: Implication of the MAGI-1b/PTEN
signalosome in stabilization of adherens junctions and suppression
of invasiveness. FASEB J. 19:115–117. 2005.PubMed/NCBI
|
|
31.
|
Langlois MJ, Bergeron S, Bernatchez G,
Boudreau F, Saucier C, Perreault N, Carrier JC and Rivard N: The
PTEN phosphatase controls intestinal epithelial cell polarity and
barrier function: role in colorectal cancer progression. PLoS One.
5:e157422010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Snietura M, Jaworska M, Mlynarczyk-Liszka
J, Goraj-Zajac A, Piglowski W, Lange D, Wozniak G, Nowara E and
Suwinski R: PTEN as a prognostic and predictive marker in
postoperative radiotherapy for squamous cell cancer of the head and
neck. PLoS One. 7:e333962012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Hildebrandt MA, Lippman SM, Etzel CJ, Kim
E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK and Wu X: Genetic
variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck
cancer patient second primary tumor/recurrence risk and response to
retinoid chemoprevention. Clin Cancer Res. 18:3705–3713. 2012.
View Article : Google Scholar : PubMed/NCBI
|
